

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 317 156
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88310507.4

(51) Int. Cl.⁴: G01N 33/569 , G01N 33/577

(22) Date of filing: 08.11.88

(30) Priority: 09.11.87 US 118498

(43) Date of publication of application:
24.05.89 Bulletin 89/21

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI NL SE

(71) Applicant: Becton Dickinson and Company
One Becton Drive
Franklin Lakes New Jersey 07417-1880(US)

(72) Inventor: Loken, Michael R.
29 San Juan Court
Los Altos, California(US)
Inventor: Sha, Virendra O.
21816 Alcazar Avenue
Cupertino, California(US)

(74) Representative: Ruffles, Graham Keith et al
MARKS & CLERK 57-60 Lincoln's Inn Fields
London WC2A 3LS(GB)

(54) Method to determine the composition of human bone marrow samples.

(57) A method and kit for identification of the lineages and stages of hematopoietic cells in a sample wherein the cells are treated with labeled monoclonal antibodies selected to distinguish between each lineage and maturational stages within each lineage.

EP 0 317 156 A1

METHOD TO DETERMINE THE COMPOSITION OF BONE MARROW SAMPLES

Field of the Invention

The present invention relates to the detection and analysis of hematopoietic cells in a sample, and more particularly relates to a method for the detection and analysis of immature and mature cells of different lineages in a bone marrow sample using labeled monoclonal antibodies and the light scattering properties of the cells.

Background of the Invention

Bone marrow is a complex tissue. Principally, marrow is the site for the differentiation and maturation of hematopoietic cells. From pluripotent stem cells, a number of cell lineages differentiate. The primary components among these lineages include: the lymphoid (B, T and NK cells), the erythroid (red blood cells) and the myeloid line (basophils, neutrophils, eosinophils, megakaryocytes and macrophages). At any given time, each of these lineages typically is present in a marrow sample.

Once differentiated, each of the various lineages mature through several stages. Maturation occurs in the marrow and elsewhere. For example, in the erythroid line, the red blood cell begins in marrow as a blast cell having a defined morphology. From that stage to the reticulocyte stage, a number of additional morphological changes occur throughout a number of stages culminating with the extrusion of the nucleus to form the reticulocyte. The reticulocyte then is released to the blood where it undergoes its final maturational change to become an erythrocyte. Other lineages undergo similar development, although the number of stages of development and the location may differ (e.g. immature T cells begin to develop in marrow but the primary location for maturation and differentiation is in the thymus). By examining a sample of bone marrow, therefore, one can identify not only the various lineages within the sample but also the several stages within each lineage.

It is important to be able to identify the lineages and/or developmental stages in a sample. The results may provide an indication of a clinical condition. For example, in a patient with anemia, in order to treat the cause of the condition one must know whether it is the result of a destruction of red cells in the blood or the result of a failure of the blast cells to mature. By examining the marrow, the presence (or absence) of stem cells, blasts and reticulocytes in normal amounts can rule out (or confirm) a diagnosis. Thus, by distinguishing a

change from the "normal" condition, abnormal events can be diagnosed.

To identify the various lineages and developmental stages, one must examine a sample in great detail. It is known that each lineage and each stage within a lineage has certain defined morphological characteristics. Thus, the current practice is to take a sample of marrow by either aspiration or biopsy, stain it and examine it under a light microscope. Such a procedure is subjective, time-intensive, semi-quantitative and may require multiple stainings in order to obtain gross results.

In addition to gross morphological changes that occur with maturation and differentiation, other detailed changes occur in gene expression. A number of studies have described the appearance (or disappearance) during maturation of a variety of such cell surface antigens in a single lineage (e.g., normal erythrocytes) and for a single antigen expressed on several lineages during their maturational process. See, e.g., Loken et al., Flow Cytometric Analysis of Human Bone Marrow: I. Normal Erythroid Development, Blood, 69:255-263 (1987), and see Civin et al., Antigenic Analysis of Hematopoiesis. VI. Flow Cytometric Characterization of MY-10-positive Progenitor Cells in Normal Human Bone Marrow, Exp. Hematol., 15:10-17 (1987) respectively. Because of the cellular heterogeneity of cells within marrow, the use of markers to detect cell surface antigens is not fully sufficient to distinguish between lineages.

Thus, at present, there is no known means to identify and distinguish between lineages and stages of development in single procedure. Such a method would provide a unique and rapid technique for the diagnosis of abnormal hematopoietic conditions.

Brief Description of the Invention

The present invention is directed to a method and kit for the identification and analysis of lineages and stages in normal hematopoietic cells. In accordance with one embodiment of the invention, a sample of bone marrow is taken from an individual. The sample is treated to provide a second sample comprising essentially only leukocytes. A first monoclonal antibody is labeled with a first fluorochrome. The first monoclonal antibody is selected so that it reacts with substantially all leukocytes. A second monoclonal antibody is labeled with a second fluorochrome. The second monoclonal antibody is selected so that it reacts with a subpopulation of leukocytes

(e.g., monocytes and granulocytes). The first fluorochrome and second fluorochrome are selected so that each has a similar excitation energy level but have distinct emission spectra.

A mixture of the second sample, first fluorochrome labeled monoclonal antibody and second fluorochrome labeled monoclonal antibody then is prepared so as to cause the leukocytes in the second mixture to become labeled with the first monoclonal antibody and the subpopulation of leukocytes to become labeled with the second monoclonal antibody. The mixture then is analyzed by flow cytometry so as to distinguish lineages by cell size and granularity, and at the same time, the distribution of the binding of the first and second antibodies on the cells is recorded. The combination of all four parameters provides data sufficient to distinguish between each lineage and stages within each lineage. The data may be stored in a data collection means, such as a computer.

Description of the Drawings

Fig. 1 is a contour plot of forward light scatter versus side (or "right angle") light scatter for a sample of normal human bone marrow analyzed by flow cytometry;

Fig. 2 is a contour plot of cells in normal human bone marrow labeled with Anti-Leu-M1(PE) and Anti-HLe-1(FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1; and

Figs. 3-5 are contour plots of cells in normal human bone marrow labeled with various monoclonal antibodies coupled to PE and labeled with Anti-HLe-1(FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1.

Detailed Description of the Invention

Bone marrow aspirates were obtained from normal adults. Although bone marrow was the source of hematopoietic cells in the following examples, it should be apparent to those skilled in the art that hematopoietic cells also may be isolated from the blood. It is not necessary to alter the method of invention to identify cells from this source.

Low density leucocytes (obtained by density gradient centrifugation using 1.077 g/cm³, Ficoll-Hypaque, Pharmacia, Piscataway, NJ) were washed in RPMI 1640 (GIBCO) containing 10% fetal bovine serum and aliquoted for im-

munofluorescent staining. Low density leukocytes were used to form the first sample. It should be apparent to those skilled in the art, however, that whole blood or marrow aspirates may be used. In such cases, ammonium chloride, for example, may be used to prepare the first sample.

Low density marrow leukocytes were suspended at a concentration of 10⁷ per ml. In those experiments where both antibodies were directly conjugated to the fluorochrome, the first antibody was added to 10⁶ cells using an amount of antibody which gave maximal fluorescence. The cells were incubated on ice for 20 minutes. The cells were then pelleted and washed with RPMI 1640 buffer (at least 5 times the staining volume) before adding the second antibody. After 20 minutes on ice, the cells were again washed with buffer, then fixed in 1% paraformaldehyde.

In experiments where only one directly fluorochrome conjugated antibody was available, a four step procedure was used. The cells were first reacted with unconjugated antibody. Following the wash step, the cells were reacted with rat anti-mouse Kappa (PE), incubated on ice, and washed. The cells were then exposed to 10% normal mouse serum to block free binding sites of the second-step antibody. The cells were then stained with the second (directly conjugated) monoclonal antibody, washed and fixed as before.

For three-color analysis, cells were reacted first with unconjugated antibody followed by rat anti-mouse Kappa-APC second step antibody. Cells were washed, reacted with 10% normal mouse serum, followed by PE-conjugated and FITC-conjugated antibodies for 20 minutes, washed and fixed as before.

Fluorescein isothiocyanate (FITC) conjugated and/or phycoerythrin (PE) conjugated directly or indirectly CD3(Leu-4), CD10(CALLA), CD11b(Leu-15), CD14(Leu-M3), CD15(Leu-11), CD19(Leu-12), CD20(Leu-16), CD45R(Leu-18), mouse IgG₁, mouse IgG₂, rat-anti-mouse Kappa, rat-anti-mouse Kappa-allophycocyanin (APC), and purified CD34-(HPCA-1) were obtained from Becton Dickinson Immunocytometry Systems, Mountain View, Ca. Anti-glycophorin (10F7) was a kind gift from Dr. R. Langlois, Livermore, CA.

Unstained cells, IgG₁-FITC, IgG₂-PE, and rat anti-mouse Kappa-APC labeled cells were included as controls.

Initially, bone marrow aspirates, prepared as above, were analyzed by flow cytometry. Presently known and available, flow cytometers are useful for measuring cell volume, forward light scatter and/or side light scatter. These parameters can then be used to separate lineages based upon their optical or physical characteristics.

Briefly, forward light scatter (FLS) provides a

measurement of cell size. (Cell volume similarly measures cell size and an instrument so equipped may be used alternatively.) Side light scatter (SLS), on the other hand, approximates the "granularity" of the cell. SLS measures light reflected from the cell and is a function of the presence (or absence) of structures in the cell such as the nucleus and/or granules. Taken together, FLS and SLS can be used to aid in distinguishing between cells of different types.

In addition to FLS and SLS, flow cytometers include one or more, usually two, fluorescent channels. These channels are used to distinguish cells marked with fluorochromes which can be excited to emit light at different wave lengths. Separate antibodies labeled with distinct fluorochromes may be used to distinguish between cell types based on their expression of different cell surface antigens. By combining all four parameters together (i.e., FLS, SLS, FL1 and FL2), the lineages and their stages can be distinguished in four dimensional space.

Flow cytometric analyses were performed using a FACStarTM for two color immunofluorescence and FACS 440TM for three color immunofluorescence (Becton Dickinson Immunocytometry Systems, Mountain View, CA). The argon ion laser was operated at 488nm using 200 mW of power. FITC emission was collected with a 530/30 BP filter, while PE emission was collected through a 585/42 BP filter. Three-color immunofluorescence was performed using a HeNe laser of 633 nm, 40 mW, along with an argon laser as described above. APC emission was collected with a 660/20 BP filter. 50,000 events was collected in list mode on a Consort 30 Data Management System (Becton Dickinson). This permitted reanalysis of the data to demonstrate the correlation between the different colors of immunofluorescence for populations of cells identified by forward and right-angle light scattering. For all contour plots, the lowest level was 3 events with contours drawn at 4, 6, 8, 10, 16, 32, 64, 128.

For a more detailed description of the use and meaning of these parameters, see Loken, Cell Surface Antigen and Morphological Characterization of Leucocyte Populations by Flow Cytometry, in Monoclonal Antibodies, Churchill Livingstone (P. Beverley ed.), 1986. Although the following cell analyses were performed by flow cytometry, it should be apparent to one skilled in the art that fluorescent light microscopy may be used alternatively to determine cell size, granularity and fluorescence.

Referring to Fig. 1, it will be seen that three distinct populations of cells appear to be distinguished by the physical parameters of forward and right angle light scattering. These windows have been labeled "LYMPH", "BLAST" and "GRAN".

The remaining material generally comprises debris (i.e., ruptured cells and cell or other fragments).

Although Fig. 1 (and indeed all the remaining figures) is shown in 2-dimensional space, it should be apparent that this is done solely for the purpose of presenting the description of the invention in viewable form. It is not the intent to limit the invention to 2-D space; in fact, in the preferred embodiment, the measurements (i.e., FLS, SLS, FL1 and FL2) are taken in 4-D space.

In order to identify the various lineages that comprise normal bone marrow, a first monoclonal antibody was selected that would identify substantially all leukocytes in the sample. CD45 is an antigen found on substantially all leukocytes. (The "CD" or cluster designation was defined by the International Workshops on Human Differentiation Antigens. The parallel "Leu" system was defined by researchers at Stanford University.) By selecting a monoclonal antibody for this antigen, leukocytes can be labeled. Anti-HLe-1 is one such monoclonal antibody. Another such antibody is LCA (Coulter Electronics, Inc.). Anti-HLe-1 is sold commercially both purified and bound to (FITC). If a pure anti-CD45 antibody is used, it may be conjugated to a fluorochrome (e.g., FITC or PE) by means known to those skilled in the art.

A second monoclonal antibody was selected to identify a subpopulation of leukocyte lineages. In the preferred embodiment, the second monoclonal antibody identifies two lineages of leukocytes: namely monocytes and granulocytes. These lineages are identified by the CD15 antigen. By selecting a monoclonal antibody for this antigen, these two lineages can be identified. Anti-Leu-M1 is one such anti-CD15 antibody, and another is Myl.

While the preferred second monoclonal antibody is anti-CD15 and more specifically Anti-Leu-M1, it should be apparent to those skilled in the art from the Figures and following examples that other monoclonal antibodies may be used so long as they distinguish between the various lineages and maturational stages. For example, anti-CD11b, anti-CD16 and anti-CD19 (i.e., Anti-Leu-15, Anti-Leu-11 and Anti-Leu-12) all function to discriminate lineages and stages. Accordingly, these and other monoclonal antibodies referred to in the examples may be used in place of anti-CD45 (or Anti-Leu-M1).

Anti-Leu-M1 is commercially available in purified form but may be reacted with a second step (PE) conjugated antibody by means known to those skilled in the art in order to be paired with Anti-HLe-1(FITC). PE is chosen because it has a wavelength of excitation substantially similar to that of FITC but emits in a different spectrum. Once selected, the fluorochrome labeled first and second

monoclonal antibodies can be combined with the sample as previously described. Anti-HLe-1(FITC) and Anti-Leu-M1(PE) are the preferred first and second monoclonal antibodies respectively.

Once the physical parameters of the cells in the sample are known as measured by FLS and SLS, gates may be established for each population in order to continue to view the invention in 2-D space. The gate will effectively exclude information from analysis for all cells outside the gate. When the gates are set for "LYMPH", "BLAST" and "GRAN" sequentially using Anti-HLe-1(FITC) and Anti-Leu-M1(PE), each lineage of cells is discernible as are the several stages of each lineage.

Referring to Fig. 2, the "LYMPH" window of bone marrow cells contains a mixture of lymphoid cells (population 2 pre-B cells, population 3 mature lymphoid cells) and mature erythrocytes (population 1a), along with nucleated erythroid precursor cells (population 1a). The "BLAST" window contains immature and mature monocytes (population 4), and immature cells of various blood cell lineages (population 1b early erythroid, 5a early neutrophils and population 6 blast cells). The "GRAN" window consists entirely of maturing granulocytes (population 5b). These results may be confirmed by light microscopic examination of the cells in accordance with standard staining procedures as described in Loken et al., *supra*.

To further confirm that the lineages identified in Fig. 2 were as described, a series of flow cytometry analyses were done with monoclonal antibodies specific for each lineage.

To detect erythrocytes, human bone marrow cells were reacted with anti-glycophorin(PE), an antibody that identified erythroid cells, and with Anti-HLe-1(FITC). The correlation between these two markers, gated on forward and side light scattering, is shown in Fig. 3A. In the "LYMPH" window, GPA^+CD45^- mature erythroid cells (population 1a) were easily distinguished from GPA^+CD45^+ lymphoid cells (population 2,3). There were no GPA^+ cells in the "GRAN" window.

In the "BLAST" window, distinct strongly GPA^+ early erythroid cells (population 1b) were discriminated from cells expressing intermediate amount of GPA . See Fig. 3A. CD45 expression progressively decreased as cells became committed to the erythroid lineage, with increased expression of GPA .

To detect T lymphocytes, normal bone marrow cells were reacted with Anti-Leu-4(PE), a CD3 pan T lymphocyte monoclonal antibody, and Anti-HLe-1(FITC). See Fig. 3B. All $CD3^+$ T lymphoid cells (population 3a) were found in "LYMPH" light scattering window, with intense co-expression of CD45.

To detect B lymphocytes, bone marrow cells were reacted with Anti-Leu-12(PE) (CD19) in combination with Anti-HLe-1(FITC) to identify all B

lymphoid cells, including both immature (population 2) and mature developmental stages (population 3b). The correlation between these two antigens is shown in Fig. 3D. All $CD19^+$ B lymphoid cells were confined to "LYMPH" window. These B lineage cells had three distinct levels of CD45 expression: $CD19^+CD45^{+++}$ (population 3b), $CD19^+CD45^{++}$, and $CD19^+CD45^+$ (population 2). In order to further discriminate maturational differences among B lineage cells, bone marrow cells were stained with CD45 in combination with two other monoclonal antibodies: Anti-CALLA(PE), (CD10) an antibody which identifies immature B lymphoid cells (not shown) or Anti-Leu-16(PE), (CD20), which identifies late B cells. Immature B cells expressing CD10 and intermediate levels of CD45 were identified in population 2.

To detect NK cells, bone marrow cells were stained with Anti-HLe-1(FITC) in combination with either Anti-Leu-11(PE) (CD16) or Anti-Leu-15(PE) (CD11b). These monoclonal antibodies identify NK cells (population 3c) within the "LYMPH" light scattering window. The cells identified by these antibodies within the "LYMPH" light scattering window were bright for $CD45^{+++}$. (Figs. 4A and 4B.) The cells in the "BLAST" and "GRAN" windows which were labeled with CD16 and CD11b were monomyeloid cells, and are discussed below.

Cells of the monocytic lineage were identified by staining bone marrow cells with either CD11b or Anti-Leu-M3(PE) (CD14), monoclonal antibodies that bind to mature and maturing monocytes (population 4). The correlated expression of these two markers with CD45 are shown in Figs. 4B and 5A.

Cells of the monocytic lineage were found only in the "BLAST" light scattering window and therefore could be distinguished from cells belonging to other lineages. There were no $CD14^+$ cells in the "LYMPH" window, while a small percentage of cells in the "GRAN" window were $CD14^+$ (Fig. 5A).

The expression of CD11b antigens on the monocyte lineage could also be identified within the "BLAST" light scattering window. The convex shape of the bivariate plot (Fig. 4B, "BLAST") suggests that the expression of CD11b precedes the change in intensity of CD45 on the maturing monocytes (population 4). The highly correlated expression of CD14 and CD45 indicates that the change in intensity of CD45 during monocytic maturation coincides with the expression of CD14. Other studies have shown that CD11b precedes CD14 expression during monocyte development. The cells expressing CD11b found in the "LYMPH" window, Figure 4B, were shown above to be NK cells (population 3c).

Development of myeloid cells was assessed by staining bone marrow cells with several monoclonal

antibodies including CD15, CD11b, CD16 in combination with CD45. CD15 is intensely expressed on granulocytes (population 5a & b) and dimly expressed on monocytes (population 4) (Fig. 2). All maturing granulocytes with the "GRAN" window (population 5b) were intensely positive for CD15 and were intermediately positive for CD45. Within the "BLAST" gate, the more immature myeloid cells (myelocytes, promyelocytes) were brightly positive for CD15 and could be distinguished from the monocytes which were less positive for CD 15 but had higher levels of CD45 (population 4) (Fig. 2).

CD11b is expressed later during myeloid development than CD15. Only a portion of the "GRAN" cells (population 5b) expressed CD11b but all expressed CD15. Even fewer cells within the "GRAN" window reacted with CD16 (Fig. 4A). The cells within the "BLAST" window which reacted with CD11b (population 4) (Fig. 4B) were predominantly monocytes since they expressed slightly higher levels of CD45.

All cells capable of forming hematopoietic colonies express the human progenitor cell antigen, CD34. The correlated expression of CD34 and CD45 on progenitor cells is shown in Fig. 5B. The CD34⁺ cells (population 6) were dimly positive for CD45. From previous studies it has been shown that approximately half of the CD34 positive cells are B lymphoid cells (population 2). These CD34⁺ immature B lymphoid cells were found in the "LYMPH" window and expressed CD19 and CD10. These cells were the same ones which were identified and discussed above, with the CD19 and CD10 B lineage markers shown in Fig. 3D. However, the remainder of CD34⁺ cells including myeloid and erythroid progenitors (population 6) which form colonies in *in vitro* assays were present in "BLAST" window (Fig. 5B) also expressing a low level of CD45.

In summary, the erythroid cells within the "LYMPH" light scattering window were easily distinguished from other cells within this window by their expression of GPA. The GPA⁺ erythroid cells, ranging from intermediate normoblast to the reticulocyte stage (population 1a), expressed little or no CD45. In contrast, the mature lymphocytes within this light scattering window, including CD3⁺ T cells (population 3a), CD16⁺ and CD11b⁺ NK cells (population 3c) and CD20⁺ mature B cells (population 3b) all expressed large amounts of the CD45 antigen.

The only other cells in this light scattering window were immature B lymphocytes (population 2), which expressed lesser amounts of CD45 than their mature descendants.

All of the cells within the "LYMPH" light scattering gate can be accounted for using these mon-

oclonal antibodies. This window includes mature T (population 3a), B (population 3b) and NK (population 3c) lymphocytes as well as maturing erythroid (population 1a) and B lymphoid (population 2) cells which can be distinguished based on the amounts of CD45 expressed on their cell surfaces. No cells of the myeloid lineages appear within this light scattering window.

Three populations of cells within the "BLAST" light scattering window were distinguished based on the intensity of CD45 and CD15 antigen expression. The cells with the lowest CD45 antigen expression (CD45[±]) were erythroid (population 1b), as identified by their expression of GPA. (Fig. 2B) The cells in this window which expressed the highest amount of CD45 were monocytic (population 4), as evidenced by the co-expression of the monocytic-specific CD14 antigen. These brighter CD45⁺ cells also expressed high levels of CD11b and intermediate amounts of CD15 antigens. The cells in the "BLAST" window which expressed intermediate amounts of CD45 were further subdivided by their expression of other cell surface antigens. CD15 divided these intermediate CD45⁺ cells into two populations. The bright CD15⁺ cells were committed to the neutrophil lineage (population 5a), including promyelocytes and myelocytes. The remaining CD15⁻, CD45⁺ cells include the CD34⁺ cells since CD15 and CD34 do not overlap in marrow. Thus, the progenitor cells (population 6), as identified in a positive manner by CD34⁺, were also detected by the combination of CD45 and CD15.

All of the cells within the "GRAN" window were characterized as having granules in their cytoplasm and having low levels of CD45. CD15 labeled all of these cells, while CD11b or CD16 identified many fewer cells. CD14 identified minor populations of these "GRAN" window cells. These cells constituted different maturational stages of the neutrophil lineage (population 5b) with corresponding differences in myeloid antigen expression.

The *in vitro* assayed progenitor cells (population 6) and presumably the pluripotent stem cells are found in the "BLAST" light scattering window. These cells express low levels of CD45 on their surfaces. As cells are committed to the erythroid lineage, their CD45 expression decreases as they begin expressing erythroid antigens such as GPA. CD45 expression decreases progressively with further maturation of these cells accompanied by a decrease in forward light scattering.

As progenitor cells (population 6) become committed to the B lineage (population 2) they maintain CD34 expression and begin expressing CD10 and CD19. This is accompanied by a decrease in their forward light scattering cell size while they maintain a low level of expression of CD45. As the B lineage cells continue to mature, they lose CD34 and in-

cr ase expression of CD45. The final stag s of B lymphoid maturation (population 3b) ar characterized by a further increase in CD45 expression, acquisition of CD20, and loss of CD10.

Once cells become committed to the monocyte lineage (4), they begin to express CD11b, followed by an increase in CD45 levels accompanied by the acquisition of CD14. The maturing monocytes also express CD15 but in lower amounts than granulocytes.

The commitment of progenitor cells (population 6) to the granulocytic maturation (population 5b) does not cause a change in CD15 expression. Although several other antigens become expressed on this lineage during the maturation process, the level of CD45 expression remains low and constant.

These and other embodiments of the invention may suggest themselves to those skilled in the art. Accordingly, this disclosure should not be taken in a limiting sense.

Claims

1. A method for the detection and identification of different lineages and stages of cell development in a sample of hematopoietic cells comprising the steps of isolating the sample from the blood or bone marrow of an individual, reacting the sample with a first monoclonal antibody and a second monoclonal antibody, wherein said first and second monoclonal antibodies are directly or indirectly conjugated with different fluorochromes having distinct emission spectra, to form a mixture and analyzing the mixture by flow cytometry to identify cell size, granularity and fluorescence characteristics of the cells in the sample.

2. A method according to Claim 1 wherein the first monoclonal antibody is selected so as to label essentially all leukocytes.

3. A method according to Claim 2 wherein the first monoclonal antibody is anti-CD45.

4. A method according to any preceding Claim, wherein the second monoclonal antibody is selected so as to label a subpopulation of leukocytes.

5. A method according to Claim 4 wherein the second monoclonal antibody is selected from the group consisting of anti-CD15, anti-CD16, anti-CD10, anti-CD34, anti-CD20, anti-CD19, anti-CD14, anti-CD3 and anti-CD11b.

6. A method according to Claim 5 wherein the second monoclonal antibody is anti-CD15.

7. A method for the detection and identification of different lineages and stages of cell development in a h matopoietic cell sample of bone marrow comprising the steps of isolating the sample from an individual, reacting the sample with a first

fluorochrome labelled monoclonal antibody that will react with substantially all leukocytes and a second fluorochrome labelled monoclonal antibody that will react with a subpopulation of leukocytes to form a mixture and analyzing the mixture by flow cytometry to identify cell size, granularity and fluorescence characteristics of the cells in the sample.

8. A method according to Claim 7 wherein the first fluorochrome labelled monoclonal antibody is Anti-HLe-1(FITC).

9. A method according to Claim 7 or 8 wherein the second fluorochrome labelled monoclonal antibody is selected from the group consisting of Anti-Leu-M1(PE), Anti-Leu-11(PE) and Anti-Leu-15(PE).

10. A method according to Claim 9 wherein the second fluorochrome labelled monoclonal antibody is Anti-Leu-M1.




FIG.1




FIG.2




FIG.3




FIG.4




FIG.5



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	EP-A-0 219 309 (SMITHKLINE BECKMAN CORP.) * Page 34, example 8, lines 1-33; page 35, lines 31-33; example 7; claims *	1,2,4,7	G 01 N 33/569 G 01 N 33/577
A	EP-A-0 132 064 (BECTON, DICKINSON & CO.) * Pages 16-24; claims 1-5 *	1,7,9	
X	US-A-4 599 304 (L. LANIER et al.) * Claim 1; column 2, column 3, Lines 1-28 *	1,9	
A	US-A-4 677 061 (L.M. ROSE et al.) * Columns 2-4; claims 1-6 *	1	
A	US-A-4 607 007 (L. LANIER et al.) * Claim 1; abstract *	1,9	
A	EP-A-0 224 134 (BOEHRINGER)		
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			G 01 N C 12 P
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27-02-1989	Examiner MEYLAERTS H.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 317 156 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (43) Date of publication of patent specification: **21.10.92** (51) Int. Cl.⁵: **G01N 33/569, G01N 33/577**
(21) Application number: **88310507.4**
(22) Date of filing: **08.11.88**

(54) **Method for analysis of hematopoietic cells in a sample.**

(30) Priority: **09.11.87 US 118498**

(43) Date of publication of application:
24.05.89 Bulletin 89/21

(45) Publication of the grant of the patent:
21.10.92 Bulletin 92/43

(94) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI NL SE

(56) References cited:
EP-A- 0 132 064 EP-A- 0 219 309
EP-A- 0 224 134 US-A- 4 599 304
US-A- 4 607 007 US-A- 4 677 061

BLOOD, vol. 69, 1987; LOKEN et al., pp.
255-263

(73) Proprietor: **Becton Dickinson and Company**
One Becton Drive
Franklin Lakes New Jersey 07417-1880(US)

(72) Inventor: **Loken, Michael R.**
29 San Juan Court
Los Altos, CA(US)
Inventor: **Sha, Virendra O.**
21816 Alcazar Avenue
Cupertino, CA(US)

(74) Representative: **Ruffles, Graham Keith et al**
MARKS & CLERK 57-60 Lincoln's Inn Fields
London WC2A 3LS(GB)

EP 0 317 156 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

Field of the Invention

The present invention relates to the detection and analysis of hematopoietic cells in a sample, and more particularly relates to a method for the detection and analysis of immature and mature cells of different lineages in a bone marrow sample using labeled monoclonal antibodies and the light scattering properties of the cells.

Background of the Invention

Bone marrow is a complex tissue. Principally, marrow is the site for the differentiation and maturation of hematopoietic cells. From pluripotent stem cells, a number of cell lineages differentiate. The primary components among these lineages include: the lymphoid (B, T and NK cells), the erythroid (red blood cells) and the myeloid line (basophils, neutrophils, eosinophils, megakaryocytes and macrophages). At any given time, each of these lineages typically is present in a marrow sample.

Once differentiated, each of the various lineages mature through several stages. Maturation occurs in the marrow and elsewhere. For example, in the erythroid line, the red blood cell begins in marrow as a blast cell having a defined morphology. From that stage to the reticulocyte stage, a number of additional morphological changes occur throughout a number of stages culminating with the extrusion of the nucleus to form the reticulocyte. The reticulocyte then is released to the blood where it undergoes its final maturational change to become an erythrocyte. Other lineages undergo similar development, although the number of stages of development and the location may differ (e.g. immature T cells begin to develop in marrow but the primary location for maturation and differentiation is in the thymus). By examining a sample of bone marrow, therefore, one can identify not only the various lineages within the sample but also the several stages within each lineage.

It is important to be able to identify the lineages and/or developmental stages in a sample. The results may provide an indication of a clinical condition. For example, in a patient with anemia, in order to treat the cause of the condition one must know whether it is the result of a destruction of red cells in the blood or the result of a failure of the blast cells to mature. By examining the marrow, the presence (or absence) of stem cells, blasts and reticulocytes in normal amounts can rule out (or confirm) a diagnosis. Thus, by distinguishing a change from the "normal" condition, abnormal events can be diagnosed.

To identify the various lineages and devel-

opmental stages, one must examine a sample in great detail. It is known that each lineage and each stage within a lineage has certain defined morphological characteristics. Thus, the current practice is to take a sample of marrow by either aspiration or biopsy, stain it and examine it under a light microscope. Such a procedure is subjective, time-intensive, semi-quantitative and may require multiple stainings in order to obtain gross results.

In addition to gross morphological changes that occur with maturation and differentiation, other detailed changes occur in gene expression. A number of studies have described the appearance (or disappearance) during maturation of a variety of such cell surface antigens in a single lineage (e.g., normal erythrocytes) and for a single antigen expressed on several lineages during their maturational process. See, e.g., Loken et al., *Flow Cytometric Analysis of Human Bone Marrow: I. Normal Erythroid Development*, *Blood*, 69:255-263 (1987), and see Civin et al., *Antigenic Analysis of Hematopoiesis. VI. Flow Cytometric Characterization of MY-10-positive Progenitor Cells in Normal Human Bone Marrow*, *Exp. Hematol.*, 15:10-17 (1987) respectively. Because of the cellular heterogeneity of cells within marrow, the use of markers to detect cell surface antigens is not fully sufficient to distinguish between lineages.

The use of labelled monoclonal antibodies to monitor activated and non-activated natural killer cell subpopulations is known from US 4 599 034.

The use of labelled monoclonal antibodies to distinguish multiple subpopulations of cells is known from EP-A-219 309.

Thus, at present, there is no known means to identify and distinguish between lineages and stages of development in single procedure. Such a method would provide a unique and rapid technique for the diagnosis of abnormal hematopoietic conditions.

Brief Description of the Invention

The present invention is directed to a method for the identification and analysis of lineages and maturation stages in normal hematopoietic cells as claimed. In accordance with one embodiment of the invention, a sample of bone marrow is taken from an individual. The sample is treated to provide a second sample comprising essentially only leukocytes. A first monoclonal antibody is labeled with a first fluorochrome. The first monoclonal antibody is selected so that it reacts with substantially all leukocytes. A second monoclonal antibody is labeled with a second fluorochrome. The second monoclonal antibody is selected so that it reacts with a subpopulation of leukocytes (e.g., monocytes and granulocytes). The first fluorochrome and second

fluorochrome are selected so that each has a similar excitation energy level but have distinct emission spectra.

A mixture of the second sample, first fluorochrome labeled monoclonal antibody and second fluorochrome labeled monoclonal antibody then is prepared so as to cause the leukocytes in the second mixture to become labeled with the first monoclonal antibody and the subpopulation of leukocytes to become labeled with the second monoclonal antibody. The mixture then is analyzed by flow cytometry so as to distinguish lineages by cell size and granularity, and at the same time, the distribution of the binding of the first and second antibodies on the cells is recorded. The combination of all four parameters provides data sufficient to distinguish between each lineage and stages within each lineage. The data may be stored in a data collection means, such as a computer.

Description of the Drawings

Fig. 1 is a contour plot of forward light scatter versus side (or "right angle") light scatter for a sample of normal human bone marrow analyzed by flow cytometry;

Fig. 2 is a contour plot of cells in normal human bone marrow labeled with Anti-Leu-M1(PE) and Anti-HLe-1(FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1; and

Figs. 3-5 are contour plots of cells in normal human bone marrow labeled with various monoclonal antibodies coupled to PE and labeled with Anti-HLe-1(FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1.

Detailed Description of the Invention

Bone marrow aspirates were obtained from normal adults. Although bone marrow was the source of hematopoietic cells in the following examples, it should be apparent to those skilled in the art that hematopoietic cells also may be isolated from the blood. It is not necessary to alter the method of invention to identify cells from this source.

Low density leucocytes (obtained by density gradient centrifugation using 1.077 g/cm³, Ficoll-Hypaque, Pharmacia, Piscataway, NJ) were washed in RPMI 1640 (GIBCO) containing 10% fetal bovine serum and aliquoted for immunofluorescent staining. Low-density leukocytes were used to form the first sample. It should be apparent to those skilled in the art, however, that

whole blood or marrow aspirates may be used. In such cases, ammonium chloride, for example, may be used to prepare the first sample.

Low density marrow leukocytes were suspended at a concentration of 10⁷ per ml. In those experiments where both antibodies were directly conjugated to the fluorochrome, the first antibody was added to 10⁶ cells using an amount of antibody which gave maximal fluorescence. The cells were incubated on ice for 20 minutes. The cells were then pelleted and washed with RPMI 1640 buffer (at least 5 times the staining volume) before adding the second antibody. After 20 minutes on ice, the cells were again washed with buffer, then fixed in 1% paraformaldehyde.

In experiments where only one directly fluorochrome conjugated antibody was available, a four step procedure was used. The cells were first reacted with unconjugated antibody. Following the wash step, the cells were reacted with rat anti-mouse Kappa (PE), incubated on ice, and washed. The cells were then exposed to 10% normal mouse serum to block free binding sites of the second-step antibody. The cells were then stained with the second (directly conjugated) monoclonal antibody, washed and fixed as before.

For three-color analysis, cells were reacted first with unconjugated antibody followed by rat anti-mouse Kappa-APC second step antibody. Cells were washed, reacted with 10% normal mouse serum, followed by PE-conjugated and FITC-conjugated antibodies for 20 minutes, washed and fixed as before.

Fluorescein isothiocyanate (FITC) conjugated and/or phycoerythrin (PE) conjugated directly or indirectly CD3(Leu-4), CD10(CALLA), CD11b(Leu-15), CD14(Leu-M3), CD15(Leu-m1), CD16(Leu-11), CD19(Leu-12), CD20(Leu-16), CD45R(Leu-18), mouse IgG₁, mouse IgG₂, rat-anti-mouse Kappa, rat-anti-mouse Kappa-allophycocyanin (APC), and purified CD34(HPCA-1) were obtained from Becton Dickinson Immunocytometry Systems, Mountain View, Ca. Anti-glycophorin (10F7) was a kind gift from Dr. R. Langlois, Livermore, CA.

Unstained cells, IgG₁-FITC, IgG₂-PE, and rat anti-mouse Kappa-APC labeled cells were included as controls.

Initially, bone marrow aspirates, prepared as above, were analyzed by flow cytometry. Presently known and available, flow cytometers are useful for measuring cell volume, forward light scatter and/or side light scatter. These parameters can then be used to separate lineages based upon their optical or physical characteristics.

Briefly, forward light scatter (FLS) provides a measurement of cell size. (Cell volume similarly measures cell size and an instrument so equipped may be used alternatively.) Side light scatter (SLS),

on the other hand, approximates the "granularity" of the cell. SLS measures light reflected from the cell and is a function of the presence (or absence) of structures in the cell such as the nucleus and/or granules. Taken together, FLS and SLS can be used to aid in distinguishing between cells of different types.

In addition to FLS and SLS, flow cytometers include one or more, usually two, fluorescent channels. These channels are used to distinguish cells marked with fluorochromes which can be excited to emit light at different wave lengths. Separate antibodies labeled with distinct fluorochromes may be used to distinguish between cell types based on their expression of different cell surface antigens. By combining all four parameters together (i.e., FLS, SLS, FL1 and FL2), the lineages and their stages can be distinguished in four dimensional space.

Flow cytometric analyses were performed using a FACStar™ for two color immunofluorescence and FACS 440™ for three color immunofluorescence (Becton Dickinson Immunocytometry Systems, Mountain View, CA). The argon ion laser was operated at 488nm using 200 mW of power. FITC emission was collected with a 530/30 BP filter, while PE emission was collected through a 585/42 BP filter. Three-color immunofluorescence was performed using a HeNe laser of 633 nm, 40 mW, along with an argon laser as described above. APC emission was collected with a 660/20 BP filter. 50,000 events was collected in list mode on a Consort 30 Data Management System (Becton Dickinson). This permitted reanalysis of the data to demonstrate the correlation between the different colors of immunofluorescence for populations of cells identified by forward and right-angle light scattering. For all contour plots, the lowest level was 3 events with contours drawn at 4, 6, 8, 10, 16, 32, 64, 128.

For a more detailed description of the use and meaning of these parameters, see Loken, Cell Surface Antigen and Morphological Characterization of Leucocyte Populations by Flow Cytometry, in Monoclonal Antibodies, Churchill Livingstone (P. Beverley ed.), 1986.

Referring to Fig. 1, it will be seen that three distinct populations of cells appear to be distinguished by the physical parameters of forward and right angle light scattering. These windows have been labeled "LYMPH", "BLAST" and "GRAN". The remaining material generally comprises debris (i.e., ruptured cells and cell or other fragments).

Although Fig. 1 (and indeed all the remaining figures) is shown in 2-dimensional space, it should be apparent that this is done solely for the purpose of presenting the description of the invention in viewable form. It is not the intent to limit the

invention to 2-D space; in fact, in the preferred embodiment, the measurements (i.e., FLS, SLS, FL1 and FL2) are taken in 4-D space.

In order to identify the various lineages that comprise normal bone marrow, a first monoclonal antibody was selected that would identify substantially all leukocytes in the sample. CD45 is an antigen found on substantially all leukocytes. (The "CD" or cluster designation was defined by the International Workshops on Human Differentiation Antigens. The parallel "Leu" system was defined by researchers at Stanford University.) By selecting a monoclonal antibody for this antigen, leukocytes can be labeled. Anti-HLe-1 is one such monoclonal antibody. Another such antibody is LCA (Coulter Electronics, Inc.). Anti-HLe-1 is sold commercially both purified and bound to (FITC). If a pure anti-CD45 antibody is used, it may be conjugated to a fluorochrome (e.g., FITC or PE) by means known to those skilled in the art.

A second monoclonal antibody was selected to identify a subpopulation of leukocyte lineages. In the preferred embodiment, the second monoclonal antibody identifies two lineages of leukocytes: namely monocytes and granulocytes. These lineages are identified by the CD15 antigen. By selecting a monoclonal antibody for this antigen, these two lineages can be identified. Anti-Leu-M1 is one such anti-CD15 antibody, and another is Myl.

While the preferred second monoclonal antibody is anti-CD15 and more specifically Anti-Leu-M1, it should be apparent to those skilled in the art from the Figures and following examples that other monoclonal antibodies may be used so long as they distinguish between the various lineages and maturational stages. For example, anti-CD11b, anti-CD16 and anti-CD19 (i.e., Anti-Leu-15, Anti-Leu-11 and Anti-Leu-12) all function to discriminate lineages and stages. Accordingly, these and other monoclonal antibodies referred to in the examples may be used in place of anti-CD45 (or Anti-Leu-M1).

Anti-Leu-M1 is commercially available in purified form but may be reacted with a second step (PE) conjugated antibody by means known to those skilled in the art in order to be paired with Anti-HLe-1(FITC). PE is chosen because it has a wavelength of excitation substantially similar to that of FITC but emits in a different spectrum. Once selected, the fluorochrome labeled first and second monoclonal antibodies can be combined with the sample as previously described. Anti-HLe-1(FITC) and Anti-Leu-M1(PE) are the preferred first and second monoclonal antibodies respectively.

Once the physical parameters of the cells in the sample are known as measured by FLS and SLS, gates may be established for each population

in order to continue to view the invention in 2-D space. The gate will effectively exclude information from analysis for all cells outside the gate. When the gates are set for "LYMPH", "BLAST" and "GRAN" sequentially using Anti-HLe-1(FITC) and Anti-Leu-M1(PE), each lineage of cells is discernible as are the several stages of each lineage.

Referring to Fig. 2, the "LYMPH" window of bone marrow cells contains a mixture of lymphoid cells (population 2 pre-B cells, population 3 mature lymphoid cells) and mature erythrocytes (population 1a), along with nucleated erythroid precursor cells (population 1a). The "BLAST" window contains immature and mature monocytes (population 4), and immature cells of various blood cell lineages (population 1b early erythroid, 5a early neutrophils and population 6 blast cells). The "GRAN" window consists entirely of maturing granulocytes (population 5b). These results may be confirmed by light microscopic examination of the cells in accordance with standard staining procedures as described in Loken et al., *supra*.

To further confirm that the lineages identified in Fig. 2 were as described, a series of flow cytometry analyses were done with monoclonal antibodies specific for each lineage.

To detect erythrocytes, human bone marrow cells were reacted with anti-glycophorin(PE), an antibody that identified erythroid cells, and with Anti-HLe-1(FITC). The correlation between these two markers, gated on forward and side light scattering, is shown in Fig. 3A. In the "LYMPH" window, $GPA^+/CD45^-$ mature erythroid cells (population 1a) were easily distinguished from $GPA^+/CD45^+$ lymphoid cells (population 2,3). There were no GPA^+ cells in the "GRAN" window.

In the "BLAST" window, distinct strongly GPA^+ early erythroid cells (population 1b) were discriminated from cells expressing intermediate amount of GPA . See Fig. 3A. $CD45$ expression progressively decreased as cells became committed to the erythroid lineage, with increased expression of GPA .

To detect T lymphocytes, normal bone marrow cells were reacted with Anti-Leu-4(PE), a CD3 pan T lymphocyte monoclonal antibody, and Anti-HLe-1(FITC). See Fig. 3B. All $CD3^+$ T lymphoid cells (population 3a) were found in "LYMPH" light scattering window, with intense co-expression of $CD45$.

To detect B lymphocytes, bone marrow cells were reacted with Anti-Leu-12(PE) ($CD19$) in combination with Anti-HLe-1(FITC) to identify all B lymphoid cells, including both immature (population 2) and mature developmental stages (population 3b). The correlation between these two antigens is shown in Fig. 3D. All $CD19^+$ B lymphoid cells were confined to "LYMPH" window. These B lineage cells had three distinct levels of $CD45$ expression: $CD19^+/CD45^{+++}$ (population 3b), $CD19^+/CD45^{++}$,

and $CD19^+/CD45^+$ (population 2). In order to further discriminate maturational differences among B lineage cells, bone marrow cells were stained with $CD45$ in combination with two other monoclonal antibodies: Anti-CALLA(PE), ($CD10$) an antibody which identifies immature B lymphoid cells (not shown) or Anti-Leu-16(PE), ($CD20$), which identifies late B cells. Immature B cells expressing $CD10$ and intermediate levels of $CD45$ were identified in population 2.

To detect NK cells, bone marrow cells were stained with Anti-HLe-1(FITC) in combination with either Anti-Leu-11(PE) ($CD16$) or Anti-Leu-15(PE) ($CD11b$). These monoclonal antibodies identify NK cells (population 3c) within the "LYMPH" light scattering window. The cells identified by these antibodies within the "LYMPH" light scattering window were bright for $CD45^{+++}$. (Figs. 4A and 4B.) The cells in the "BLAST" and "GRAN" windows which were labeled with $CD16$ and $CD11b$ were monomyeloid cells, and are discussed below.

Cells of the monocytic lineage were identified by staining bone marrow cells with either $CD11b$ or Anti-Leu-M3(PE) ($CD14$), monoclonal antibodies that bind to mature and maturing monocytes (population 4). The correlated expression of these two markers with $CD45$ are shown in Figs. 4B and 5A.

Cells of the monocytic lineage were found only in the "BLAST" light scattering window and therefore could be distinguished from cells belonging to other lineages. There were no $CD14^+$ cells in the "LYMPH" window, while a small percentage of cells in the "GRAN" window were $CD14^+$ (Fig. 5A).

The expression of $CD11b$ antigens on the monocyte lineage could also be identified within the "BLAST" light scattering window. The convex shape of the bivariate plot (Fig. 4B, "BLAST") suggests that the expression of $CD11b$ precedes the change in intensity of $CD45$ on the maturing monocytes (population 4). The highly correlated expression of $CD14$ and $CD45$ indicates that the change in intensity of $CD45$ during monocytic maturation coincides with the expression of $CD14$. Other studies have shown that $CD11b$ precedes $CD14$ expression during monocyte development. The cells expressing $CD11b$ found in the "LYMPH" window, Figure 4B, were shown above to be NK cells (population 3c).

Development of myeloid cells was assessed by staining bone marrow cells with several monoclonal antibodies including $CD15$, $CD11b$, $CD16$ in combination with $CD45$. $CD15$ is intensely expressed on granulocytes (population 5a & b) and dimly expressed on monocytes (population 4) (Fig. 2). All maturing granulocytes with the "GRAN" window (population 5b) were intensely positive for $CD15$ and were intermediately positive for $CD45$. Within

the "BLAST" gate, the more immature myeloid cells (myelocytes, promyelocytes) were brightly positive for CD15 and could be distinguished from the monocytes which were less positive for CD 15 but had higher levels of CD45 (population 4) (Fig. 2).

CD11b is expressed later during myeloid development than CD15. Only a portion of the "GRAN" cells (population 5b) expressed CD11b but all expressed CD15. Even fewer cells within the "GRAN" window reacted with CD16 (Fig. 4A). The cells within the "BLAST" window which reacted with CD11b (population 4) (Fig. 4B) were predominantly monocytes since they expressed slightly higher levels of CD45.

All cells capable of forming hematopoietic colonies express the human progenitor cell antigen, CD34. The correlated expression of CD34 and CD45 on progenitor cells is shown in Fig. 5B. The CD34⁺ cells (population 6) were dimly positive for CD45. From previous studies it has been shown that approximately half of the CD34 positive cells are B lymphoid cells (population 2). These CD34⁺ immature B lymphoid cells were found in the "LYMPH" window and expressed CD19 and CD10. These cells were the same ones which were identified and discussed above, with the CD19 and CD10 B lineage markers shown in Fig. 3D. However, the remainder of CD34⁺ cells including myeloid and erythroid progenitors (population 6) which form colonies in *in vitro* assays were present in "BLAST" window (Fig. 5B) also expressing a low level of CD45.

In summary, the erythroid cells within the "LYMPH" light scattering window were easily distinguished from other cells within this window by their expression of GPA. The GPA⁺ erythroid cells, ranging from intermediate normoblast to the reticulocyte stage (population 1a), expressed little or no CD45. In contrast, the mature lymphocytes within this light scattering window, including CD3⁺ T cells (population 3a), CD16⁺ and CD11b⁺ NK cells (population 3c) and CD20⁺ mature B cells (population 3b) all expressed large amounts of the CD45 antigen.

The only other cells in this light scattering window were immature B lymphocytes (population 2), which expressed lesser amounts of CD45 than their mature descendants.

All of the cells within the "LYMPH" light scattering gate can be accounted for using these monoclonal antibodies. This window includes mature T (population 3a), B (population 3b) and NK (population 3c) lymphocytes as well as maturing erythroid (population 1a) and B lymphoid (population 2) cells which can be distinguished based on the amounts of CD45 expressed on their cell surfaces. No cells of the myeloid lineages

appear within this light scattering window.

Three populations of cells within the "BLAST" light scattering window were distinguished based on the intensity of CD45 and CD15 antigen expression. The cells with the lowest CD45 antigen expression (CD45[±]) were erythroid (population 1b), as identified by their expression of GPA. (Fig. 2B) The cells in this window which expressed the highest amount of CD45 were monocytic (population 4), as evidenced by the co-expression of the monocytic-specific CD14 antigen. These brighter CD45⁺ cells also expressed high levels of CD11b and intermediate amounts of CD15 antigens. The cells in the "BLAST" window which expressed intermediate amounts of CD45 were further subdivided by their expression of other cell surface antigens. CD15 divided these intermediate CD45⁺ cells into two populations. The bright CD15⁺ cells were committed to the neutrophil lineage (population 5a), including promyelocytes and myelocytes. The remaining CD15⁻, CD45⁺ cells include the CD34⁺ cells since CD15 and CD34 do not overlap in marrow. Thus, the progenitor cells (population 6), as identified in a positive manner by CD34⁺, were also be detected by the combination of CD45 and CD15.

All of the cells within the "GRAN" window were characterized as having granules in their cytoplasm and having low levels of CD45. CD15 labeled all of these cells, while CD11b or CD16 identified many fewer cells. CD14 identified minor populations of these "GRAN" window cells. These cells constituted different maturational stages of the neutrophil lineage (population 5b) with corresponding differences in myeloid antigen expression.

The *in vitro* assayed progenitor cells (population 6) and presumably the pluripotent stem cells are found in the "BLAST" light scattering window. These cells express low levels of CD45 on their surfaces. As cells are committed to the erythroid lineage, their CD45 expression decreases as they begin expressing erythroid antigens such as GPA. CD45 expression decreases progressively with further maturation of these cells accompanied by a decrease in forward light scattering.

As progenitor cells (population 6) become committed to the B lineage (population 2) they maintain CD34 expression and begin expressing CD10 and CD19. This is accompanied by a decrease in their forward light scattering cell size while they maintain a low level of expression of CD45. As the B lineage cells continue to mature, they lose CD34 and increase expression of CD45. The final stages of B lymphoid maturation (population 3b) are characterized by a further increase in CD45 expression, acquisition of CD20, and loss of CD10.

Once cells become committed to the monocyte lineage (4), they begin to express CD11b, followed by an increase in CD45 levels accompanied by the

acquisition of CD14. The maturing monocytes also express CD15 but in lower amounts than granulocytes.

The commitment of progenitor cells (population 6) to the granulocytic maturation (population 5b) does not cause a change in CD15 expression. Although several other antigens become expressed on this lineage during the maturation process, the level of CD45 expression remains low and constant.

Claims

1. A method for the detection of different lineages and maturational stages of hematopoietic cells in a sample from the blood or bone marrow of an individual, the method comprising the steps of reacting the sample with a first monoclonal antibody and a second monoclonal antibody to form a mixture, wherein said first monoclonal antibody is selected so as to react with substantially all leukocytes and the second monoclonal antibody is selected so as to react with a subpopulation of leukocytes and wherein said first and second monoclonal antibodies are conjugated directly or indirectly with different fluorochromes having distinct emission spectra, and analysing the mixture by flow cytometry to identify cell size, granularity and fluorescence of the cells in the sample, wherein cell size, granularity and relative fluorescence intensity are used to distinguish between lineages and between maturational stages in each of the lineages.
2. A method according to Claim 2 wherein the first monoclonal antibody is anti-CD45.
3. A method according to Claim 1 or 2, wherein the second monoclonal antibody is selected from the group consisting of anti-CD15, anti-CD16, anti-CD10, anti-CD34, anti-CD20, anti-CD19, anti-CD14, anti-CD3 and anti-CD11b.
4. A method according to Claim 3 wherein the second monoclonal antibody is anti-CD15.
5. A method according to Claim 1, wherein the sample is a sample of bone marrow.
6. A method according to Claim 5 wherein the first fluorochrome labelled monoclonal antibody is Anti-HLe-1(FITC).
7. A method according to Claim 5 or 6 wherein the second fluorochrome labelled monoclonal antibody is selected from the group consisting of Anti-Leu-M1(PE), Anti-Leu-11(PE) and Anti-

Leu-15(PE).

8. A method according to Claim 7 where in the second fluorochrome labelled monoclonal antibody is Anti-Leu-M1.

Patentansprüche

1. Verfahren für den Nachweis von unterschiedlichen Stämmen und Reifungszuständen von hämatopoietischen Zellen in einer Probe aus dem Blut oder Knochenmark eines Individuums, wobei das Verfahren die Stufen der Reaktion der Probe mit einem ersten monoklonalen Antikörper und einem zweiten monoklonalen Antikörper unter Bildung einer Mischung, worin dieser erste monoklonale Antikörper so ausgewählt ist, daß er mit praktisch allen Leukocyten reagiert, und der zweite monoklonale Antikörper so ausgewählt ist, daß er mit einer Subpopulation von Leukocyten reagiert, und worin diese ersten und zweiten monoklonalen Antikörper direkt oder indirekt mit unterschiedlichen Fluorochromen mit verschiedenen Emissionsspektren konjugiert sind, und die Analyse der Mischung durch Strömungs-Cytometrie zur Identifizierung der Zellgröße, Granularität und Fluoreszenz der Zellen in der Probe umfaßt, wobei Zellgröße, Granularität und Fluoreszenzintensität zur Unterscheidung zwischen Stämmen und zwischen Reifungszuständen in jedem der Stämme benutzt werden.
2. Verfahren nach Anspruch 1, worin der erste monoklonale Antikörper anti-CD45 ist.
3. Verfahren nach Anspruch 1 oder 2, worin der zweite monoklonale Antikörper aus der aus anti-CD15, anti-CD16, anti-CD10, anti-CD34, anti-CD20, anti-CD19, anti-CD14, anti-CD3, und anti-CD11b bestehenden Gruppe ausgewählt wird.
4. Verfahren nach Anspruch 3, worin der zweite monoklonale Antikörper anti-CD15 ist.
5. Verfahren nach Anspruch 1, worin die Probe eine Knochenmarkprobe ist.
6. Verfahren nach Anspruch 5, worin der erste mit Fluorochrom markierte monoklonale Antikörper Anti-HLe-1(FITC) ist.
7. Verfahren nach Anspruch 5 oder 6, worin der zweite mit Fluorochrom markierte monoklonale Antikörper aus der aus Anti-Leu-M1(PE), Anti-Leu-11(PE) und Anti-Leu-15(PE) bestehenden Gruppe ausgewählt wird.

8. Verfahren nach Anspruch 7, worin der zweite mit Fluorochrom markierte monoklonale Antikörper Anti-Leu-M1 ist.

Revendications

1. Une méthode pour détecter différentes lignées et stades de maturation de cellules hématopoïétiques dans un échantillon de sang ou de moelle osseuse d'un individu, la méthode comprenant les étapes de mise en réaction de l'échantillon avec un premier anticorps monoclonal et un deuxième anticorps monoclonal pour former un mélange, dans laquelle ledit premier anticorps monoclonal est sélectionné de sorte à réagir avec pratiquement tous les leucocytes et le deuxième anticorps monoclonal est sélectionné de sorte à réagir avec un sous-groupe de leucocytes, et dans laquelle lesdits premier et deuxième anticorps monoclonaux sont conjugués directement ou indirectement avec différents fluorochromes ayant des spectres d'émission distincts, ainsi que d'analyse du mélange par cytométrie de flux pour identifier la taille de la cellule, la granularité et la fluorescence des cellules dans l'échantillon, la taille de la cellule, la granularité et l'intensité relative de fluorescence étant utilisés pour faire la distinction entre les lignées et entre les stades de maturation dans chacune des lignées. 10 15 20 25 30
2. Une méthode selon la revendication 2, dans laquelle le premier anticorps monoclonal est l'anti-CD45. 35
3. Une méthode selon les revendications 1 ou 2, dans laquelle le deuxième anticorps monoclonal est choisi dans le groupe constitué par l'anti-CD15, l'anti-CD16, l'anti-CD10, l'anti-CD34, l'anti-CD20, l'anti-CD19, l'anti-CD14, l'anti-CD3 et l'anti-CD11b. 40
4. Une méthode selon la revendication 3, dans laquelle le deuxième anticorps monoclonal est l'anti-CD15. 45
5. Une méthode selon la revendication 1, dans laquelle l'échantillon est un échantillon de moelle osseuse. 50
6. Une méthode selon la revendication 5, dans laquelle le premier anticorps monoclonal marqué au fluorochrome est l'Anti-Hle-1(FITC). 55
7. Une méthode selon les revendications 5 ou 6, dans laquelle le deuxième anticorps monoclonal marqué au fluorochrome est choisi dans le

groupe constitué par l'Anti-Leu-M1 (PE), l'Anti-Leu-11 (PE) et l'Anti-Leu-15 (PE).

8. Une méthode selon la revendication 7, dans laquelle le deuxième anticorps monoclonal marqué au fluorochrome est l'Anti-Leu-M1.




FIG.1




FIG.2




FIG.3




FIG.4




FIG.5

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 317 156 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the opposition decision:
12.11.1997 Bulletin 1997/46

(51) Int Cl.⁶: **G01N 33/569**, G01N 33/577

(45) Mention of the grant of the patent:
21.10.1992 Bulletin 1992/43

(21) Application number: **88310507.4**

(22) Date of filing: **08.11.1988**

(54) Method for analysis of hematopoietic cells in a sample

Verfahren zur Analyse hämatopoietischer Zellen in einer Probe

Méthode pour analyser des cellules hématopoïétiques d'un échantillon

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI NL SE

(30) Priority: **09.11.1987 US 118498**

(43) Date of publication of application:
24.05.1989 Bulletin 1989/21

(73) Proprietor: **Becton, Dickinson and Company**
Franklin Lakes, New Jersey 07417-1880 (US)

(72) Inventors:
• **Loken, Michael R.**
Los Altos, CA (US)
• **Shah, Virendra O.**
Cupertino, CA (US)

(74) Representative: **Ruffles, Graham Keith et al**
MARKS & CLERK,
57-60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(56) References cited:

EP-A- 0 132 064	EP-A- 0 219 309
EP-A- 0 224 134	EP-B- 0 193 356
US-A- 4 599 304	US-A- 4 607 007
US-A- 4 645 738	US-A- 4 677 061

- **BLOOD**, vol. 69, 1987; **LOKEN et al.**, pp. 255-263
- **Ault et al.**, J. Exp. Med. 161, pp 1488-1502, June 1985
- **Loken et al.**, Blood 70, pp 1316-1325, November 1987
- **Civin et al.**, Exp. Hematol. 15, pp 10-17, 1987
- **Horan et al.**, Proc. Natl. Acad. Sci. USA 83, pp 8361-8365, 1986
- **Strauss et al.**, Exp. Hematol. 14, pp 935-945, 1986
- **HOKLAND ET AL.**; Blood 64, pp 662-666, 1984

EP 0 317 156 B2

Description

Field of the Invention

The present invention relates to the detection and analysis of hematopoietic cells in a sample, and more particularly relates to a method for the detection and analysis of immature and mature cells of different lineages in a bone marrow sample using labeled monoclonal antibodies and the light scattering properties of the cells.

Background of the Invention

Bone marrow is a complex tissue. Principally, marrow is the site for the differentiation and maturation of hematopoietic cells. From pluripotent stem cells, a number of cell lineages differentiate. The primary components among these lineages include: the lymphoid (B, T and NK cells), the erythroid (red blood cells) and the myeloid line (basophils, neutrophils, eosinophils, megakaryocytes and macrophages). At any given time, each of these lineages typically is present in a marrow sample.

Once differentiated, each of the various lineages mature through several stages. Maturation occurs in the marrow and elsewhere. For example, in the erythroid line, the red blood cell begins in marrow as a blast cell having a defined morphology. From that stage to the reticulocyte stage, a number of additional morphological changes occur throughout a number of stages culminating with the extrusion of the nucleus to form the reticulocyte. The reticulocyte then is released to the blood where it undergoes its final maturational change to become an erythrocyte. Other lineages undergo similar development, although the number of stages of development and the location may differ (e.g. immature T cells begin to develop in marrow but the primary location for maturation and differentiation is in the thymus). By examining a sample of bone marrow, therefore, one can identify not only the various lineages within the sample but also the several stages within each lineage.

It is important to be able to identify the lineages and/or developmental stages in a sample. The results may provide an indication of a clinical condition. For example, in a patient with anemia, in order to treat the cause of the condition one must know whether it is the result of a destruction of red cells in the blood or the result of a failure of the blast cells to mature. By examining the marrow, the presence (or absence) of stem cells, blasts and reticulocytes in normal amounts can rule out (or confirm) a diagnosis. Thus, by distinguishing a change from the "normal" condition, abnormal events can be diagnosed.

To identify the various lineages and developmental stages, one must examine a sample in great detail. It is known that each lineage and each stage within a lineage has certain defined morphological characteristics. Thus,

the current practice is to take a sample of marrow by either aspiration or biopsy, stain it and examine it under a light microscope. Such a procedure is subjective, time-intensive, semi-quantitative and may require multiple stainings in order to obtain gross results.

In addition to gross morphological changes that occur with maturation and differentiation, other detailed changes occur in gene expression. A number of studies have described the appearance (or disappearance) during maturation of a variety of such cell surface antigens in a single lineage (e.g., normal erythrocytes) and for a single antigen expressed on several lineages during their maturational process. See, e.g., Loken *et al.*, Flow Cytometric Analysis of Human Bone Marrow: I. Normal Erythroid Development, *Blood*, 69:255-263 (1987), and see Civin *et al.*, Antigenic Analysis of Hematopoiesis. VI. Flow Cytometric Characterization of MY-10-positive Progenitor Cells in Normal Human Bone Marrow, *Exp. Hematol.*, 15:10-17 (1987) respectively. Because of the cellular heterogeneity of cells within marrow, the use of markers to detect cell surface antigens is not fully sufficient to distinguish between lineages.

The use of labelled monoclonal antibodies to monitor activated and non-activated natural killer cell subpopulations is known from US 4 599 034.

The use of labelled monoclonal antibodies to distinguish multiple subpopulations of cells is, known from EP-A-219 309, and see also EP-A 193,356.

By way of illustration, the application of such techniques to the phenotyping of recovering lymphoid cell populations after marrow transplantation is described in *J. Exp. Med.*, volume 161, June 1985 at pages 1483 to 1502. FLE-HLE antibody, which labels all blood leukocytes, and PE-Leu-M3, which labels monocytes, were used to set a flow cytometer gate based on the forward and right-angle light scatter parameters, to include all of the brightly coloured HLE-labelled lymphocytes, and to exclude as much as possible the unlabelled erythrocytes and the Leu-M3-labelled monocytes. Samples from a patient were then analyzed using twenty-four pairs of labelled monoclonal antibodies.

Thus, at present, there is no known means to identify and distinguish between lineages and stages of development in single procedure. Such a method would provide a unique and rapid technique for the diagnosis of abnormal hematopoietic conditions.

Brief Description of the Invention

The present invention is directed to a method for the identification and analysis of lineages and maturation stages in normal hematopoietic cells as claimed. In accordance with one embodiment of the invention, a sample of bone marrow is taken from an individual. The sample is treated to provide a second sample comprising essentially only leukocytes. A first monoclonal antibody is labeled with a first fluorochrome. The first monoclonal antibody is selected so that it reacts with sub-

may order!

stantially all leukocytes. A second monoclonal antibody is labeled with a second fluorochrome. The second monoclonal antibody is selected so that it reacts with a subpopulation of leukocytes (e.g., monocytes and granulocytes). The first fluorochrome and second fluorochrome are selected so that each has a similar excitation energy level but have distinct emission spectra.

A mixture of the second sample, first fluorochrome labeled monoclonal antibody and second fluorochrome labeled monoclonal antibody then is prepared so as to cause the leukocytes in the second mixture to become labeled with the first monoclonal antibody and the subpopulation of leukocytes to become labeled with the second monoclonal antibody. The mixture then is analyzed by flow cytometry so as to distinguish lineages by cell size and granularity, and at the same time, the distribution of the binding of the first and second antibodies on the cells is recorded. The combination of all four parameters provides data sufficient to distinguish between each lineage and stages within each lineage. The data may be stored in a data collection means, such as a computer.

Description of the Drawings

Fig. 1 is a contour plot of forward light scatter versus side (or "right angle") light scatter for a sample of normal human bone marrow analyzed by flow cytometry;

Fig. 2 is a contour plot of cells in normal human bone marrow labeled with Anti-Leu-M1(PE) and Anti-HLe-1(FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1; and

Figs. 3-5 are contour plots of cells in normal human bone marrow labeled with various monoclonal antibodies coupled to PE and labeled with Anti-HLe-1 (FITC) as analyzed by flow cytometry with gates set to exclude all cells but those that appear in the "LYMPH", "BLAST" or "GRAN" window of Fig. 1.

Detailed Description of the Invention

Bone marrow aspirates were obtained from normal adults. Although bone marrow was the source of hematopoietic cells in the following examples, it should be apparent to those skilled in the art that hematopoietic cells also may be isolated from the blood. It is not necessary to alter the method of invention to identify cells from this source.

Low density leucocytes (obtained by density gradient centrifugation using 1.077 g/cm³, Ficoll-Hypaque, Pharmacia, Piscataway, NJ) were washed in RPMI 1640 (GIBCO) containing 10% fetal bovine serum and aliquoted for immunofluorescent staining. Low-density leukocytes were used to form the first sample. It should be apparent to those skilled in the art, however, that whole

blood or marrow aspirates may be used. In such causes, ammonium chloride, for example, may be used to prepare the first sample.

Low density marrow leukocytes were suspended at a concentration of 10⁷ per ml. In those experiments where both antibodies were directly conjugated to the fluorochrome, the first antibody was added to 10⁶ cells using an amount of antibody which gave maximal fluorescence. The cells were incubated on ice for 20 minutes. The cells were then pelleted and washed with RPMI 1640 buffer (at least 5 times the staining volume) before adding the second antibody. After 20 minutes on ice, the cells were again washed with buffer, then fixed in 1% paraformaldehyde.

In experiments where only one directly fluorochrome conjugated antibody was available, a four step procedure was used. The cells were first reacted with unconjugated antibody. Following the wash step, the cells were reacted with rat anti-mouse Kappa (PE), incubated on ice, and washed. The cells were then exposed to 10% normal mouse serum to block free binding sites of the second-step antibody. The cells were then stained with the second (directly conjugated) monoclonal antibody, washed and fixed as before.

For three-color analysis, cells were reacted first with unconjugated antibody followed by rat anti-mouse Kappa-APC second step antibody. Cells were washed, reacted with 10% normal mouse serum, followed by PE-conjugated and FITC-conjugated antibodies for 20 minutes, washed and fixed as before.

Fluorescein isothiocyanate (FITC) conjugated and/or phycoerythrin (PE) conjugated directly or indirectly CD3(Leu-4), CD10(CALLA), CD11b(Leu-15), CD14(Leu-M3), CD15 (Leu-m1), CD16(Leu-11), CD19(Leu-12), CD20(Leu-16), CD45R(Leu-18), mouse IgG₁, mouse IgG₂, rat-anti-mouse Kappa, rat-anti-mouse Kappa-allophycocyanin (APC), and purified CD34(HPCA-1) were obtained from Becton Dickinson Immunocytometry Systems, Mountain View, Ca. Anti-glycophorin (10F7) was a kind gift from Dr. R. Langlois, Livermore, CA.

Unstained cells, IgG₁-FITC, IgG₂-PE, and rat anti-mouse Kappa-APC labeled cells were included as controls.

Initially, bone marrow aspirates, prepared as above, were analyzed by flow cytometry. Presently known and available, flow cytometers are useful for measuring cell volume, forward light scatter and/or side light scatter. These parameters can then be used to separate lineages based upon their optical or physical characteristics.

Briefly, forward light scatter (FLS) provides a measurement of cell size. (Cell volume similarly measures cell size and an instrument so equipped may be used alternatively.) Side light scatter (SLS), on the other hand, approximates the "granularity" of the cell. SLS measures light reflected from the cell and is a function of the presence (or absence) of structures in the cell such as the nucleus and/or granules. Taken together,

FLS and SLS can be used to aid in distinguishing between cells of different types.

In addition to FLS and SLS, flow cytometers include one or more, usually two, fluorescent channels. These channels are used to distinguish cells marked with fluorochromes which can be excited to emit light at different wave lengths. Separate antibodies labeled with distinct fluorochromes may be used to distinguish between cell types based on their expression of different cell surface antigens. By combining all four parameters together (*i.e.*, FLS, SLS, FL1 and FL2), the lineages and their stages can be distinguished in four dimensional space.

Flow cytometric analyses were performed using a FACStar™ for two color immunofluorescence and FACS 440™ for three color immunofluorescence (Becton Dickinson Immunocytometry Systems, Mountain View, CA). The argon ion laser was operated at 488nm using 200 mW of power. FITC emission was collected with a 530/30 BP filter, while PE emission was collected through a 585/42 BP filter. Three-color immunofluorescence was performed using a HeNe laser of 633 nm, 40 mW, along with an argon laser as described above. APC emission was collected with a 660/20 BP filter. 50,000 events was collected in list mode on a Consort 30 Data Management System (Becton Dickinson). This permitted reanalysis of the data to demonstrate the correlation between the different colors of immunofluorescence for populations of cells identified by forward and right-angle light scattering. For all contour plots, the lowest level was 3 events with contours drawn at 4, 6, 8, 10, 16, 32, 64, 128.

For a more detailed description of the use and meaning of these parameters, *see* Loken, Cell Surface Antigen and Morphological Characterization of Leucocyte Populations by Flow Cytometry, in Monoclonal Antibodies, Churchill Livingstone (P. Beverley ed.), 1986.

Referring to Fig. 1, it will be seen that three distinct populations of cells appear to be distinguished by the physical parameters of forward and right angle light scattering. These windows have been labeled "LYMPH", "BLAST" and "GRAN". The remaining material generally comprises debris (*i.e.*, ruptured cells and cell or other fragments).

Although Fig. 1 (and indeed all the remaining figures) is shown in 2-dimensional space, it should be apparent that this is done solely for the purpose of presenting the description of the invention in viewable form. It is not the intent to limit the invention to 2-D space; in fact, in the preferred embodiment, the measurements (*i.e.*, FLS, SLS, FL1 and FL2) are taken in 4-D space.

In order to identify the various lineages that comprise normal bone marrow, a first monoclonal antibody was selected that would identify substantially all leukocytes in the sample. CD45 is an antigen found on substantially all leukocytes. (The "CD" or cluster designation was defined by the International Workshops on Human Differentiation Antigens. The parallel "Leu" system was defined by researchers at Stanford University.) By

selecting a monoclonal antibody for this antigen, leukocytes can be labeled. Anti-HLe-1 is one such monoclonal antibody. Another such antibody is LCA (Coulter Electronics, Inc.). Anti-HLe-1 is sold commercially both purified and bound to (FITC). If a pure anti-CD45 antibody is used, it may be conjugated to a fluorochrome (*e.g.*, FITC or PE) by means known to those skilled in the art.

A second monoclonal antibody was selected to identify a subpopulation of leukocyte lineages. In the preferred embodiment, the second monoclonal antibody identifies two lineages of leukocytes: namely monocytes and granulocytes. These lineages are identified by the CD15 antigen. By selecting a monoclonal antibody for this antigen, these two lineages can be identified. Anti-Leu-M1 is one such anti-CD15 antibody, and another is Myl.

While the preferred second monoclonal antibody is anti-CD15 and more specifically Anti-Leu-M1, it should be apparent to those skilled in the art from the Figures and following examples that other monoclonal antibodies may be used so long as they distinguish between the various lineages and maturational stages. For example, anti-CD11b, anti-CD16 and anti-CD19 (*i.e.*, Anti-Leu-15, Anti-Leu-11 and Anti-Leu-12) all function to discriminate lineages and stages. Accordingly, these and other monoclonal antibodies referred to in the examples may be used in place of anti-CD45 (or Anti-Leu-M1).

Anti-Leu-M1 is commercially available in purified form but may be reacted with a second step (PE) conjugated antibody by means known to those skilled in the art in order to be paired with Anti-HLe-1(FITC). PE is chosen because it has a wavelength of excitation substantially similar to that of FITC but emits in a different spectrum. Once selected, the fluorochrome labeled first and second monoclonal antibodies can be combined with the sample as previously described. Anti-HLe-1 (FITC) and Anti-Leu-M1(PE) are the preferred first and second monoclonal antibodies respectively.

Once the physical parameters of the cells in the sample are known as measured by FLS and SLS, gates may be established for each population in order to continue to view the invention in 2-D space. The gate will effectively exclude information from analysis for all cells outside the gate. When the gates are set for "LYMPH", "BLAST" and "GRAN" sequentially using Anti-HLe-1 (FITC) and Anti-Leu-M1(PE), each lineage of cells is discernible as are the several stages of each lineage.

Referring to Fig. 2, the "LYMPH" window of bone marrow cells contains a mixture of lymphoid cells (population 2 pre-B cells, population 3 mature lymphoid cells) and mature erythrocytes (population 1a), along with nucleated erythroid precursor cells (population 1a). The "BLAST" window contains immature and mature monocytes (population 4), and immature cells of various blood cell lineages (population 1b early erythroid, 5a early neutrophils and population 6 blast cells). The "GRAN" window consists entirely of maturing granulo-

cytes (population 5b). These results may be confirmed by light microscopic examination of the cells in accordance with standard staining procedures as described in Loken *et al.*, *supra*.

To further confirm that the lineages identified in Fig. 2 were as described, a series of flow cytometry analyses were done with monoclonal antibodies specific for each lineage.

To detect erythrocytes, human bone marrow cells were reacted with anti-glycophorin(PE), an antibody that identified erythroid cells, and with Anti-HLe-1 (FITC). The correlation between these two markers, gated on forward and side light scattering, is shown in Fig. 3A. In the "LYMPH" window, GPA⁺/CD45⁺ mature erythroid cells (population 1a) were easily distinguished from GPA⁺/CD45⁺ lymphoid cells (population 2,3). There were no GPA⁺ cells in the "GRAN" window.

In the "BLAST" window, distinct strongly GPA⁺ early erythroid cells (population 1b) were discriminated from cells expressing intermediate amount of GPA. *See* Fig. 3A. CD45 expression progressively decreased as cells became committed to the erythroid lineage, with increased expression of GPA.

To detect T lymphocytes, normal bone marrow cells were reacted with Anti-Leu-4(PE), a CD3 pan T lymphocyte monoclonal antibody, and Anti-HLe-1(FITC). *See* Fig. 3B. All CD3⁺ T lymphoid cells population 3a) were found in "LYMPH" light scattering window, with intense co-expression of CD45.

To detect B lymphocytes, bone marrow cells were reacted with Anti-Leu-12(PE) (CD19) in combination with Anti-HLe-1(FITC) to identify all B lymphoid cells, including both immature (population 2) and mature developmental stages (population 3b). The correlation between these two antigens is shown in Fig. 3D. All CD19⁺ B lymphoid cells were confined to "LYMPH" window. These B lineage cells had three distinct levels of CD45 expression: CD19⁺/CD45⁺⁺⁺ (population 3b), CD19⁺/CD45⁺⁺, and CD19⁺/CD45⁺ (population 2). In order to further discriminate maturational differences among B lineage cells, bone marrow cells were stained with CD45 in combination with two other monoclonal antibodies: Anti-CALLA(PE), (CD10) an antibody which identifies immature B lymphoid cells (not shown) or Anti-Leu-16 (PE), (CD20), which identifies late B cells. Immature B cells expressing CD10 and intermediate levels of CD45 were identified in population 2.

To detect NK cells, bone marrow cells were stained with Anti-HLe-1(FITC) in combination with either Anti-Leu-11(PE) (CD16) or Anti-Leu-15(PE) (CD11b). These monoclonal antibodies identify NK cells (population 3c) within the "LYMPH" light scattering window. The cells identified by these antibodies within the "LYMPH" light scattering window were bright for CD45⁺⁺⁺. (Figs. 4A and 4B.) The cells in the "BLAST" and "GRAN" windows which were labeled with CD16 and CD11b were monomyeloid cells, and are discussed below.

Cells of the monocytic lineage were identified by

staining bone marrow cells with either CD11b or Anti-Leu-M3(PE) (CD14), monoclonal antibodies that bind to mature and maturing monocytes (population 4). The correlated expression of these two markers with CD45 are shown in Figs. 4B and 5A.

Cells of the monocytic lineage were found only in the "BLAST" light scattering window and therefore could be distinguished from cells belonging to other lineages. There were no CD14⁺ cells in the "LYMPH" window, while a small percentage of cells in the "GRAN" window were CD14⁺ (Fig. 5A).

The expression of CD11b antigens on the monocyte lineage could also be identified within the "BLAST" light scattering window. The convex shape of the bivariate plot (Fig. 4B, "BLAST") suggests that the expression of CD11b precedes the change in intensity of CD45 on the maturing monocytes (population 4). The highly correlated expression of CD14 and CD45 indicates that the change in intensity of CD45 during monocytic maturation coincides with the expression of CD14. Other studies have shown that CD11b precedes CD14 expression during monocyte development. The cells expressing CD11b found in the "LYMPH" window, Figure 4B, were shown above to be NK cells (population 3c).

Development of myeloid cells was assessed by staining bone marrow cells with several monoclonal antibodies including CD15, CD11b, CD16 in combination with CD45. CD15 is intensely expressed on granulocytes (population 5a & b) and dimly expressed on monocytes (population 4) (Fig. 2). All maturing granulocytes with the "GRAN" window (population 5b) were intensely positive for CD15 and were intermediately positive for CD45. Within the "BLAST" gate, the more immature myeloid cells (myelocytes, promyelocytes) were brightly positive for CD15 and could be distinguished from the monocytes which were less positive for CD 15 but had higher levels of CD45 (population 4) (Fig. 2).

CD11b is expressed later during myeloid development than CD15. Only a portion of the "GRAN" cells (population 5b) expressed CD11b but all expressed CD15. Even fewer cells within the "GRAN" window reacted with CD16 (Fig. 4A). The cells within the "BLAST" window which reacted with CD11b (population 4) (Fig. 4B) were predominantly monocytes since they expressed slightly higher levels of CD45.

All cells capable of forming hematopoietic colonies express the human progenitor cell antigen, CD34. The correlated expression of CD34 and CD45 on progenitor cells is shown in Fig. 5B. The CD34⁺ cells (population 6) were dimly positive for CD45. From previous studies it has been shown that approximately half of the CD34 positive cells are B lymphoid cells (population 2). These CD34⁺ immature B lymphoid cells were found in the "LYMPH" window and expressed CD19 and CD10. These cells were the same ones which were identified and discussed above, with the CD19 and CD10 B lineage markers shown in Fig. 3D. However, the remainder of CD34⁺ cells including myeloid and erythroid progen-

Detection
of stem cell
type by
incubation w/
various
labelled Ab
specific to
Agg on
surface
↓
Flow
Cyt.
↓
FACS

itors (population 6) which form colonies in in vitro assays were present in "BLAST" window (Fig. 5B) also expressing a low level of CD45.

In summary, the erythroid cells within the "LYMPH" light scattering window were easily distinguished from other cells within this window by their expression of GPA. The GPA⁺ erythroid cells, ranging from intermediate normoblast to the reticulocyte stage (population 1a), expressed little or no CD45. In contrast, the mature lymphocytes within this light scattering window, including CD3⁺ T cells (population 3a), CD16⁺ and CD11b NK cells (population 3c) and CD20⁺ mature B cells (population 3b) all expressed large amounts of the CD45 antigen.

The only other cells in this light scattering window were immature B lymphocytes (population 2), which expressed lesser amounts of CD45 than their mature descendants.

All of the cells within the "LYMPH" light scattering gate can be accounted for using these monoclonal antibodies. This window includes mature T (population 3a), B (population 3b) and NK (population 3c) lymphocytes as well as maturing erythroid (population 1a) and B lymphoid (population 2) cells which can be distinguished based on the amounts of CD45 expressed on their cell surfaces. No cells of the myeloid lineages appear within this light scattering window.

Three populations of cells within the "BLAST" light scattering window were distinguished based on the intensity of CD45 and CD15 antigen expression. The cells with the lowest CD45 antigen expression (CD45[±]) were erythroid (population 1b), as identified by their expression of GPA. (Fig. 2B) The cells in this window which expressed the highest amount of CD45 were monocytic (population 4), as evidenced by the co-expression of the monocytic-specific CD14 antigen. These brighter CD45⁺ cells also expressed high levels of CD11b and intermediate amounts of CD15 antigens. The cells in the "BLAST" window which expressed intermediate amounts of CD45 were further subdivided by their expression of other cell surface antigens. CD15 divided these intermediate CD45⁺ cells into two populations. The bright CD15⁺ cells were committed to the neutrophil lineage (population 5a), including promyelocytes and myelocytes. The remaining CD15⁻, CD45 cells include the CD34⁺ cells since CD15 and CD34 do not overlap in marrow. Thus, the progenitor cells (population 6), as identified in a positive manner by CD34⁺, were also detected by the combination of CD45 and CD15.

All of the cells within the "GRAN" window were characterized as having granules in their cytoplasm and having low levels of CD45. CD15 labeled all of these cells, while CD11b or CD16 identified many fewer cells. CD14 identified minor populations of these "GRAN" window cells. These cells constituted different maturational stages of the neutrophil lineage (population 5b) with corresponding differences in myeloid antigen expression.

The in vitro assayed progenitor cells (population 6)

and presumably the pluripotent stem cells are found in the "BLAST" light scattering window. These cells express low levels of CD45 on their surfaces. As cells are committed to the erythroid lineage, their CD45 expression decreases as they begin expressing erythroid antigens such as GPA. CD45 expression decreases progressively with further maturation of these cells accompanied by a decrease in forward light scattering.

As progenitor cells (population 6) become committed to the B lineage (population 2) they maintain CD34 expression and begin expressing CD10 and CD19. This is accompanied by a decrease in their forward light scattering cell size while they maintain a low level of expression of CD45. As the B lineage cells continue to mature, they lose CD34 and increase expression of CD45. The final stages of B lymphoid maturation (population 3b) are characterized by a further increase in CD45 expression, acquisition of CD20, and loss of CD10.

Once cells become committed to the monocyte lineage (4), they begin to express CD11b, followed by an increase in CD45 levels accompanied by the acquisition of CD14. The maturing monocytes also express CD15 but in lower amounts than granulocytes.

The commitment of progenitor cells (population 6) to the granulocytic maturation (population 5b) does not cause a change in CD15 expression. Although several other antigens become expressed on this lineage during the maturation process, the level of CD45 expression remains low and constant.

Claims

1. A method for the detection of different lineages and maturational stages of hematopoietic cells in a sample from the blood or bone marrow of an individual, the method comprising the steps of reacting the sample with a first monoclonal antibody and a second monoclonal antibody to form a mixture, wherein said first monoclonal antibody is selected so as to react with substantially all leukocytes and the second monoclonal antibody is selected so as to react with a subpopulation of leukocytes and wherein said first and second monoclonal antibodies are conjugated directly or indirectly with different fluorochromes having distinct emission spectra, analysing the mixture by gated flow cytometry to identify cell size, granularity and fluorescence of the cells in the sample using forward light scatter and side light scatter to establish gates for populations of lymphocytes, blast cells and granulocytes and using relative fluorescence intensity to distinguish between cell types based on their expression of different cell surface antigens, and thereby assigning cells in the sample to the lymphoid, erythroid and myeloid lineages and maturational stages in each of the lineages on the basis of cell size, granularity and relative fluorescence intensity.

Population
of stem cell
type/lineage
through
CD45[±]
labelled
Ab to
CD45[±]

2. A method according to Claim 2 wherein the first monoclonal antibody is anti-CD45.
3. A method according to Claim 1 or 2, wherein the second monoclonal antibody is selected from the group consisting of anti-CD15, anti-CD16, anti-CD10, anti-CD34, anti-CD20, anti-CD19, anti-CD14, anti-CD3 and anti-CD11b.
4. A method according to Claim 3 wherein the second monoclonal antibody is anti-CD15.
5. A method according to Claim 1, wherein the sample is a sample of bone marrow.

Patentansprüche

1. Verfahren zum Nachweis von unterschiedlichen Stämmen und Reifungszuständen von hämatopoietischen Zellen in einer Probe aus dem Blut oder Knochenmark eines Individuums, wobei das Verfahren die Stufen der Reaktion der Probe mit einem ersten monoklonalen Antikörper und einem zweiten monoklonalen Antikörper unter Bildung einer Mischung, worin dieser erste monoklonale Antikörper so ausgewählt ist, daß er mit praktisch allen Leukozyten reagiert, und der zweite monoklonale Antikörper so ausgewählt ist, daß er mit einer Subpopulation von Leukozyten reagiert, und worin diese ersten und zweiten monoklonalen Antikörper direkt oder indirekt mit unterschiedlichen Fluorochromen mit verschiedenen Emissionsspektren konjugiert sind, die Analyse der Mischung durch Kanal-Strömungs-Cytometrie zur Identifizierung der Zellgröße, Granularität und Fluoreszenz der Zellen in der Probe unter Anwendung von Vorwärts-Lichtstreuung und Seiten-Lichtstreuung zur Aufstellung von Kanälen für Populationen von Lymphocyten, nucleotierten Zellen und Granulocyten umfaßt, und wobei die relative Fluoreszenzintensität zur Unterscheidung zwischen den Zelltypen, basierend auf ihrer Expression von unterschiedlichen Zelloberflächenantigenen benutzt wird, und hierdurch Zellen in der Probe zu den Lymphoid-, Erythroid- und Myeloidstämmen und den Reifungszuständen in jedem der Stämme auf der Basis von Zellgröße, Granularität und relativer Fluoreszenzintensität zugeordnet werden.
2. Verfahren nach Anspruch 1, worin der erste monoklonale Antikörper anti-CD45 ist.
3. Verfahren nach Anspruch 1 oder 2, worin der zweite monoklonale Antikörper aus der aus anti-CD15, anti-CD16, anti-CD10, anti-CD34, anti-CD20, anti-CD19, anti-CD14, anti-CD3 und anti-CD11b bestehenden Gruppe ausgewählt wird.

4. Verfahren nach Anspruch 3, worin der zweite monoklonale Antikörper anti-CD15 ist.
5. Verfahren nach Anspruch 1, worin die Probe eine Knochenmarkprobe ist.

Revendications

1. Méthode pour détecter différentes lignées et stades de maturation de cellules hématopoïétiques dans un échantillon de sang ou de moelle osseuse d'un individu, la méthode comprenant les étapes de mise en réaction de l'échantillon avec un premier anticorps monoclonal et un deuxième anticorps monoclonal pour former un mélange, dans laquelle ledit premier anticorps monoclonal est sélectionné de sorte à réagir avec pratiquement tous les leucocytes et le deuxième anticorps monoclonal est sélectionné de sorte à réagir avec un sous-groupe de leucocytes, et dans laquelle lesdites premier et deuxième anticorps monoclonaux sont conjugués directement ou indirectement avec différents fluorochromes ayant des spectres d'émission distincts, ainsi que d'analyse du mélange par cytométrie de flux à grille pour identifier la taille de la cellule, la granularité et la fluorescence des cellules dans l'échantillon, avec utilisation de la diffusion de la lumière vers l'avant et de la diffusion latérale pour établir des grilles pour les populations de lymphocytes, de blastocytes et de granulocytes, et avec utilisation de l'intensité de la fluorescence relative pour faire la distinction entre les types de cellules sur la base de leur expression de différents antigènes de surface de la cellule, pour assigner ainsi les cellules dans l'échantillon aux lignées lymphoïdes, érythroïdes et myéloïdes, et déterminer les stades de maturation dans chacune des lignées sur la base de la taille de la cellule, de la granularité et de l'intensité de fluorescence relative.
2. Une méthode selon la revendication 2, dans laquelle le premier anticorps monoclonal est l'anti-CD45.
3. Une méthode selon les revendications 1 ou 2, dans laquelle le deuxième anticorps monoclonal est choisi dans le groupe constitué par l'anti-CD15, l'anti-CD16, l'anti-CD10, l'anti-CD34, l'anti-CD20, l'anti-CD19, l'anti-CD14, l'anti-CD3 et l'anti-CD11b.
4. Une méthode selon la revendication 3, dans laquelle le deuxième anticorps monoclonal est l'anti-CD15.
5. Une méthode selon la revendication 1, dans laquelle l'échantillon est un échantillon de moelle osseuse.




FIG.1




FIG.2




FIG.3




FIG.4




FIG.5